TELA Bio Appoints Jeffrey Blizard as President
Leadership Appointment: TELA Bio, Inc. has appointed Jeffrey Blizard as President, effective immediately, bringing extensive industry experience from his previous roles at Abiomed and other leading medtech companies.
Company Growth Focus: The leadership change is seen as a pivotal moment for TELA Bio as it aims to enhance its competitive edge in the soft-tissue reconstruction market and deepen customer relationships while driving commercial performance.
Trade with 70% Backtested Accuracy
Analyst Views on TELA
About TELA
About the author
BDX Faces Monopoly Allegations in U.S. Hernia Mesh Market, Impacting Patient Choices
- Monopoly Allegations: TELA Bio's lawsuit claims that Becton Dickinson controls approximately 65% of the U.S. permanent hernia mesh market and 77% of the resorbable mesh market, leveraging its dominance to raise costs for hospitals and limit patient choices.
- Restrictive Contracts: The complaint alleges that Becton Dickinson used overlapping, multi-year contracts with hospitals and purchasing organizations to restrict access to OviTex, resulting in TELA Bio's marginal market share despite physician preference for its product.
- Patient Impact: The lawsuit highlights a case where a surgeon was denied approval to use OviTex due to Becton Dickinson's contracts, leading to a patient's worsening condition and eventual death during surgery, illustrating the direct harm caused by these practices.
- Legal Consequences: TELA Bio seeks damages and injunctive relief to restore competition and expand choices for patients and providers, while Becton Dickinson faces over 30,000 related lawsuits, indicating escalating legal risks for the company.
Becton, Dickinson Faces Allegations of Stifling Competition in Hernia Mesh Industry
Lawsuit Filed: Tela Bio has filed a lawsuit against Becton, Dickinson, alleging anti-competitive practices in the surgical hernia mesh market, specifically targeting its OviTex product.
Allegations of Retaliation: The lawsuit claims Becton, Dickinson retaliated against hospitals for purchasing OviTex and used long-term contracts to limit competition by forcing customers to buy exclusively from them.
TELA Bio Grants 3,600 Restricted Stock Units to New Employees
- Employee Incentive Program: TELA Bio has granted 3,600 restricted stock units to three newly hired employees, aiming to attract talent through an appealing compensation package, thereby enhancing the company's competitiveness in the medical technology sector.
- Grant Details: The grant date for these restricted stock units is December 9, 2025, and they were issued under the Nasdaq Rule 5635(c)(4) inducement grant exception, indicating the company's emphasis on incentive measures during recruitment.
- Vesting Arrangement: The granted stock units will vest in equal annual installments over four years, ensuring stability among new hires during their tenure, which will help improve overall team execution and business continuity.
- Company Vision: TELA Bio focuses on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, further solidifying its position in the medical technology market.
TELA Bio Grants 3,600 Restricted Stock Units to New Employees
- Employee Incentive Program: TELA Bio has granted 3,600 restricted stock units to three newly hired employees, aiming to attract talent through an appealing compensation package, thereby enhancing the company's competitiveness in the medical technology sector.
- Grant Details: The restricted stock units were granted on December 9, 2025, under the Nasdaq Rule 5635(c)(4) inducement grant exception, ensuring that new employees vest in equal annual installments over four years, which promotes long-term retention.
- Company Strategy: By implementing this incentive measure, TELA Bio not only enhances employee loyalty but also positions itself to attract and retain key talent in the rapidly evolving medical technology market, driving innovation and business growth.
- Market Positioning: As a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, TELA Bio's initiative demonstrates its strong commitment to optimizing clinical outcomes and enhancing market competitiveness.
Alphabet Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Tuesday
Analyst Upgrades and Price Target Increases: HC Wainwright & Co. raised the price target for Zymeworks Inc. from $26 to $32 while maintaining a Buy rating. Jefferies also increased the price target for Legence Corp. from $39 to $49 and upgraded the stock from Hold to Buy.
Analyst Downgrades and Price Target Cuts: BTIG cut the price target for LifeMD Inc. from $18 to $10, while JP Morgan reduced Auna SA's target from $13.5 to $6 and downgraded it from Overweight to Neutral.
Mixed Ratings and Price Adjustments: Canaccord Genuity lowered TELA Bio Inc.'s price target from $7 to $4 but kept a Buy rating, whereas B of A Securities cut Honeywell International Inc.'s target from $265 to $205 and downgraded it from Buy to Underperform.
Other Notable Changes: Loop Capital raised Alphabet Inc.'s price target from $260 to $320 and upgraded it from Hold to Buy, while HC Wainwright & Co. increased HIVE Digital Technologies Ltd.'s target from $8 to $10, maintaining a Buy rating.
Canaccord Genuity Keeps Buy Rating on TELA Bio, Reduces Price Target to $4
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.
Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.
BDX Faces Monopoly Allegations in U.S. Hernia Mesh Market, Impacting Patient Choices
- Monopoly Allegations: TELA Bio's lawsuit claims that Becton Dickinson controls approximately 65% of the U.S. permanent hernia mesh market and 77% of the resorbable mesh market, leveraging its dominance to raise costs for hospitals and limit patient choices.
- Restrictive Contracts: The complaint alleges that Becton Dickinson used overlapping, multi-year contracts with hospitals and purchasing organizations to restrict access to OviTex, resulting in TELA Bio's marginal market share despite physician preference for its product.
- Patient Impact: The lawsuit highlights a case where a surgeon was denied approval to use OviTex due to Becton Dickinson's contracts, leading to a patient's worsening condition and eventual death during surgery, illustrating the direct harm caused by these practices.
- Legal Consequences: TELA Bio seeks damages and injunctive relief to restore competition and expand choices for patients and providers, while Becton Dickinson faces over 30,000 related lawsuits, indicating escalating legal risks for the company.
Becton, Dickinson Faces Allegations of Stifling Competition in Hernia Mesh Industry
Lawsuit Filed: Tela Bio has filed a lawsuit against Becton, Dickinson, alleging anti-competitive practices in the surgical hernia mesh market, specifically targeting its OviTex product.
Allegations of Retaliation: The lawsuit claims Becton, Dickinson retaliated against hospitals for purchasing OviTex and used long-term contracts to limit competition by forcing customers to buy exclusively from them.
TELA Bio Grants 3,600 Restricted Stock Units to New Employees
- Employee Incentive Program: TELA Bio has granted 3,600 restricted stock units to three newly hired employees, aiming to attract talent through an appealing compensation package, thereby enhancing the company's competitiveness in the medical technology sector.
- Grant Details: The grant date for these restricted stock units is December 9, 2025, and they were issued under the Nasdaq Rule 5635(c)(4) inducement grant exception, indicating the company's emphasis on incentive measures during recruitment.
- Vesting Arrangement: The granted stock units will vest in equal annual installments over four years, ensuring stability among new hires during their tenure, which will help improve overall team execution and business continuity.
- Company Vision: TELA Bio focuses on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, further solidifying its position in the medical technology market.
TELA Bio Grants 3,600 Restricted Stock Units to New Employees
- Employee Incentive Program: TELA Bio has granted 3,600 restricted stock units to three newly hired employees, aiming to attract talent through an appealing compensation package, thereby enhancing the company's competitiveness in the medical technology sector.
- Grant Details: The restricted stock units were granted on December 9, 2025, under the Nasdaq Rule 5635(c)(4) inducement grant exception, ensuring that new employees vest in equal annual installments over four years, which promotes long-term retention.
- Company Strategy: By implementing this incentive measure, TELA Bio not only enhances employee loyalty but also positions itself to attract and retain key talent in the rapidly evolving medical technology market, driving innovation and business growth.
- Market Positioning: As a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, TELA Bio's initiative demonstrates its strong commitment to optimizing clinical outcomes and enhancing market competitiveness.
Alphabet Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Tuesday
Analyst Upgrades and Price Target Increases: HC Wainwright & Co. raised the price target for Zymeworks Inc. from $26 to $32 while maintaining a Buy rating. Jefferies also increased the price target for Legence Corp. from $39 to $49 and upgraded the stock from Hold to Buy.
Analyst Downgrades and Price Target Cuts: BTIG cut the price target for LifeMD Inc. from $18 to $10, while JP Morgan reduced Auna SA's target from $13.5 to $6 and downgraded it from Overweight to Neutral.
Mixed Ratings and Price Adjustments: Canaccord Genuity lowered TELA Bio Inc.'s price target from $7 to $4 but kept a Buy rating, whereas B of A Securities cut Honeywell International Inc.'s target from $265 to $205 and downgraded it from Buy to Underperform.
Other Notable Changes: Loop Capital raised Alphabet Inc.'s price target from $260 to $320 and upgraded it from Hold to Buy, while HC Wainwright & Co. increased HIVE Digital Technologies Ltd.'s target from $8 to $10, maintaining a Buy rating.
Canaccord Genuity Keeps Buy Rating on TELA Bio, Reduces Price Target to $4
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.
Market Success: Traders utilize Benzinga Pro's resources to gain a competitive edge and improve their chances of winning in the markets daily.
